What question did this study set out to answer?

To review the roles of specific inflammatory mediators in heart failure pathogenesis and examine current biological and non-biological therapies targeting these pathways.

December 2, 2021International Journal of Molecular SciencesOpen Access

Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results

View Full Paper

Ask AI

Bookmark

Why the study?

Inflammation contributes significantly to HF development and progression, making specific anti-inflammatory treatment a novel approach to prevent and slow disease progression.

Do specific anti-inflammatory treatments targeting inflammatory mediators prevent or slow heart failure progression?

Design

Review

Authors

TSTimea Magdolna SzaboUniversitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș AFAttila FrigyUniversitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș ENE NagyUniversitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș

Discussion

Member takes

Implication

Chronic inflammation drives HF via immune-mitochondrial pathways; extends mechanistic understanding but leaves targeted therapies unproven.

Key Points

To review the roles of specific inflammatory mediators in heart failure pathogenesis and examine current biological and non-biological therapies targeting these pathways.
Synthesized experimental and clinical evidence examining inflammatory signaling in heart failure development and progression.
Assessed biological and non-biological treatment strategies targeting key inflammatory mediators, including tumor necrosis factor-alpha and interleukins 1, 6, 17, 18, and 33.
Proinflammatory signaling molecules trigger cellular dysfunction that impairs mitochondrial activity and alters calcium homeostasis, reducing myocardial contractility.
Targeted interventions against cytokines such as tumor necrosis factor-alpha and interleukins represent emerging therapeutic strategies to halt or slow disease progression.

Structured PICO

Do specific anti-inflammatory treatments targeting inflammatory mediators prevent or slow heart failure progression?

Population

Patients with heart failure and experimental models of heart failure

Intervention

Anti-inflammatory treatments targeting inflammatory mediators (tumor necrosis factor-alpha; interleukin 1, 6, 17, 18, 33)

Targeting specific inflammatory mediators represents a novel therapeutic approach to prevent and slow the progression of heart failure.

Cite This Study

Szabo et al. (2021) studied this question.

synapsesocial.com/papers/6a70c8a3fe4101aa97e04f09 https://doi.org/10.3390/ijms222313053

Topics

Heart failure Myocarditis HFrEF treatment

View Full Paper

Ask AI

Bookmark

Implication

Chronic inflammation drives HF via immune-mitochondrial pathways; extends mechanistic understanding but leaves targeted therapies unproven.

Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider